Aktueller Stellenwert der Behandlung mit Wachstumsfaktoren

Pseudarthrosen sind das Ergebnis einer gestörten Frakturheilung. Die Therapie ist komplex und erfordert das makellose Zusammenspiel zwischen mechanischen und biologischen Komponenten. Hierzu wurden in den letzten Jahren vermehrt Wachstumsfaktoren eingesetzt. Der Beitrag zeigt, warum Wachstumsfaktoren helfen können, die aktuell verfügbar sind, und worauf bei der Anwendung zu achten ist.

Schlüsselwörter

Wachstumsfaktoren - Pseudarthrose - Frakturheilungsstörung - Bone morphogenic Proteins

• Literatur

• 1 Emara KM, Diab RA, Emara AK. Recent biological trends in management of fracture non-union. World J Orthop 2015; 6: 623-628 doi:10.5312/wjo.v6.i8.623
• 2 Schlundt C, Bucher CH, Tsitsilonis S. et al. Clinical and research approaches to treat non-union fracture. Curr Osteoporos Rep 2018;
• 3 Santolini E, West R, Giannoudis PV. Risk factors for long bone fracture non-union: a stratification approach based on the level of the existing scientific evidence. Injury 2015; 46 Suppl 8: S8-S19 doi:10.1016/S0020-1383(15)30049-8
• 4 Schmidmaier G, Moghaddam A. Pseudarthrosen langer Röhrenknochen. Z Orthop Unfallchir 2015; 153: 659-674 doi:10.1055/s-0035-1558259 quiz 675–656
• 5 Oryan A, Alidadi S, Moshiri A. et al. Bone morphogenetic proteins: a powerful osteoinductive compound with non-negligible side effects and limitations. Biofactors 2014; 40: 459-481 doi:10.1002/biof.1177
• 6 Valdes MA, Thakur NA, Namdari S. et al. Recombinant bone morphogenic protein-2 in orthopaedic surgery: a review. Arch Orthop Trauma Surg 2009; 129: 1651-1657 doi:10.1007/s00402-009-0850-8
• 7 Sheth U, Simunovic N, Klein G. et al. Efficacy of autologous platelet-rich plasma use for orthopaedic indications: a meta-analysis. J Bone Joint Surg Am 2012; 94: 298-307 doi:10.2106/JBJS.K.00154
• 8 Buza JA, 3rd Einhorn T. Bone healing in 2016. Clin Cases Miner Bone Metab 2016; 13: 101-105 doi:10.11138/ccmbm/2016.13.2.101
• 9 Andia I, Martin JI, Maffulli N. Advances with platelet rich plasma therapies for tendon regeneration. Expert Opin Biol Ther 2018; 18: 389-398 doi:10.1080/14712598.2018.1424626
• 10 Kawaguchi H, Oka H, Jingushi S. et al. A local application of recombinant human fibroblast growth factor 2 for tibial shaft fractures: A randomized, placebo-controlled trial. J Bone Miner Res 2010; 25: 2735-2743 doi:10.1002/jbmr.146
• 11 Hollinger JO, Hart CE, Hirsch SN. et al. Recombinant human platelet-derived growth factor: biology and clinical applications. J Bone Joint Surg Am 2008; 90 Suppl 1: 48-54 doi:10.2106/JBJS.G.01231
• 12 DiGiovanni CW, Lin SS, Baumhauer JF. et al. Recombinant human platelet-derived growth factor-BB and beta-tricalcium phosphate (rhPDGF-BB/beta-TCP): an alternative to autogenous bone graft. J Bone Joint Surg Am 2013; 95: 1184-1192 doi:10.2106/JBJS.K.01422
• 13 Schmidmaier G, Herrmann S, Green J. et al. Quantitative assessment of growth factors in reaming aspirate, iliac crest, and platelet preparation. Bone 2006; 39: 1156-1163 doi:10.1016/j.bone.2006.05.023
• 14 White AP, Vaccaro AR, Hall JA. et al. Clinical applications of BMP-7/OP-1 in fractures, nonunions and spinal fusion. Int Orthop 2007; 31: 735-741 doi:10.1007/s00264-007-0422-x
• 15 Garrison KR, Shemilt I, Donell S. et al. Bone morphogenetic protein (BMP) for fracture healing in adults. Cochrane Database Syst Rev 2010; (06) CD006950
• 16 James AW, LaChaud G, Shen J. et al. A Review of the Clinical Side Effects of Bone Morphogenetic Protein-2. Tissue Eng Part B Rev 2016; 22: 284-297 doi:10.1089/ten.TEB.2015.0357
• 17 Moghaddam A, Thaler B, Bruckner T. et al. Treatment of atrophic femoral non-unions according to the diamond concept: Results of one- and two-step surgical procedure. J Orthop 2017; 14: 123-133 doi:10.1016/j.jor.2016.10.003
• 18 Hreha J, Krell ES, Bibbo C. Role of recombinant human bone morphogenetic protein-2 on hindfoot arthrodesis. Foot Ankle Clin 2016; 21: 793-802 doi:10.1016/j.fcl.2016.07.001
• 19 Shamie AN, Yazdanshenas H, Johnson EE. Long-term safety and efficacy of human bone morphogenetic protein (HBMP) in the treatment of resistant non-unions and failed arthrodesis. J Clin Orthop Trauma 2017; 8: 59-62 doi:10.1016/j.jcot.2016.10.008
• 20 Axelrad TW, Kakar S, Einhorn TA. New technologies for the enhancement of skeletal repair. Injury 2007; 38 Suppl 1: S49-S62 doi:10.1016/j.injury.2007.02.010
• 21 Alt V, Borgman B, Eicher A. et al. Effects of recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) in grade III open tibia fractures treated with unreamed nails-A clinical and health-economic analysis. Injury 2015; 46: 2267-2272 doi:10.1016/j.injury.2015.07.013